NCT00175019View on ClinicalTrials.gov

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

PHASE3CompletedINTERVENTIONAL
Enrollment

1,086

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Gout
Interventions
DRUG

Febuxostat

Febuxostat 80 mg, tablets, orally, once daily.

DRUG

Febuxostat

Febuxostat 120 mg, tablets, orally, once daily.

DRUG

Allopurinol

Allopurinol 100 mg or 300 mg, tablets, orally, once daily.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY